Angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-23 and is reviewed periodically as new material appears.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
=== Pharmacodynamics === Compared to shorter-chain homologues such as DOM, DOET, and DOPR, which are all potent psychedelics, DOBU has even higher affinity for the serotonin 5-HT2A receptor. It has been found to act as a potent full agonist of the serotonin 5-HT2A and 5-HT2C receptors. The drug is also a serotonin 5-HT2B receptor full agonist but with far lower potency. Additional receptor interactions have also been described. DOBU fully substitutes for DOM in rodent drug discrimination tests, albeit several-fold less potently than DOET or DOPR. In addition, DOBU robustly induces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents, and maximally does so about as strongly as other DOx drugs like DOM, DOET, DOPR, and DOC. The doses at which DOBU produces peak head twitches are similar to those of DOM and DOET. Other effects of DOBU in rodents include hyperlocomotion at lower doses, hypolocomotion at higher doses, and hypothermia at higher doses.
=== July === July 1 Recreational cannabis becomes legal in Connecticut and Virginia. Medical cannabis becomes legal in South Dakota. COVID-19 vaccination – Michigan Governor Gretchen Whitmer announces a month-long vaccination raffle in which residents can win a total of $5 million in cash (one grand prize of $2 million or three prizes of $1 million) and $500,000 total in college scholarships for children ages 12–17 years old (nine prizes of $55,000). The winners were drawn on August 4. July 2 – Hundreds of businesses are hit by a large-scale cyberattack, linked to the Russian REvil ransomware gang. July 2–5 – At least 233 people were killed and 618 people were injured in over 500 shootings nationwide during the Independence Day weekend. July 6 – 2021 New York City mayoral election – Eric Adams was declared the winner of the Democratic primary for mayor of New York City. July 7 – The Tampa Bay Lightning defeat the Montreal Canadiens (4-1) in the 2021 Stanley Cup Finals to win their second consecutive Stanley Cup. July 8 – Attorney Michael Avenatti is sentenced to 2.5 years in prison for attempting to extort Nike. July 9 Twitter suspensions – Twitter announces that they have suspended political commentator and nationalist Nick Fuentes. President Biden signs a 72-point executive order placing tighter regulations and scrutiny on major corporations in a variety of sectors, including Big Tech companies.
This behavior is somewhat peculiar to normal phase chromatography because it is governed almost exclusively by an adsorptive mechanism (i.e., analytes interact with a solid surface rather than with the solvated layer of a ligand attached to the sorbent surface; see also reversed-phase HPLC below). Adsorption chromatography is still somewhat used for structural isomer separations in both column and thin-layer chromatography formats on activated (dried) silica or alumina supports. Partition- and NP-HPLC fell out of favor in the 1970s with the development of reversed-phase HPLC because of poor reproducibility of retention times due to the presence of a water or protic organic solvent layer on the surface of the silica or alumina chromatographic media. This layer changes with any changes in the composition of the mobile phase (e.g., moisture level) causing drifting retention times. Recently, partition chromatography has become popular again with the development of Hilic bonded phases which demonstrate improved reproducibility, and due to a better understanding of the range of usefulness of the technique.
Sources: en.wikipedia.org
Spinneys, which holds a 50-year lease with a 382,900 ft² cold storage distribution centre BRF (Brasil Foods), which operates a 1.6 million sq plant producing meat products and bread-based foods under the Sadia brand. Emirates Calcium Carbonate Factory, established under a 50-year agreement to supply products for oilfield industries Palletco, a manufacturing facility under a 50-year lease agreement. Apex Engineering Industries, an AED 90 million manufacturing facility for oil, gas and defence. Abundance Solar Panel Industries, an AED 55 million solar production plant. Global logistics companies, including DHL Global Forwarding and DSV, which provide logistics and supply chain services. Azizi Developments, which signed a 50-year land lease agreement to build 12 factories with an investment of AED 1 billion. Jiangsu Overseas Cooperation Investment Co. Ltd (JOCIC), established in 2017 to manage the China-UAE Industrial Capacity Cooperation Demonstration Zone. Built-to-suit
Banana powder is a powder made from processed bananas. It is used as a component for production of milk shakes and baby foods. It is also used in the manufacture of various types of cakes and biscuits.
In beta cells, insulin release is stimulated primarily by glucose present in the blood. As circulating glucose levels rise, such as after ingesting a meal, insulin is secreted in a dose-dependent fashion. This system of release is commonly referred to as glucose-stimulated insulin secretion (GSIS). There are four key events to the triggering pathway of GSIS: GLUT dependent glucose uptake, glucose metabolism, KATP channel closure, and the opening of voltage gated calcium channels causing insulin granule fusion and exocytosis. Voltage-gated calcium channels and ATP-sensitive potassium ion channels (KATP channels) are embedded in the plasma membrane of beta cells. Under non-glucose stimulated conditions, the KATP channels are open and the voltage gated calcium channels are closed. Via the KATP channels, potassium ions move out of the cell, down their concentration gradient, making the inside of the cell more negative with respect to the outside (as potassium ions carry a positive charge). At rest, this creates a potential difference across the cell surface membrane of -70mV. When the glucose concentration outside the cell is high, glucose molecules move into the cell by facilitated diffusion, down its concentration gradient through glucose transporters (GLUT). Rodent beta cells primarily express the GLUT2 isoform, whereas human beta cells, although also expressing GLUT2, mainly make use of GLUT1 and GLUT3 isoforms. Since beta cells use glucokinase to catalyze the first step of glycolysis, metabolism only occurs around physiological blood glucose levels and above.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.